# US 2025/0082694 A1 · Probiotics for use in boosting the immune system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082694 A1
- Document ID: US20250082694A1
- Status: Published application
- Kind: A1
- Application number: 18/580,713
- Filed: 2022-07-13
- Published: 2025-03-13
- Earliest claimed: 2021-07-22
- Assignees: International N&H Denmark Aps
- Applicants: International N&H Denmark Aps
- Inventors: MARKUS LEHTINEN; SINIKKA ANNELI LATVALA; LIISA LEHTORANTA
- Web page: https://patentgrep.com/patent/US20250082694A1

## CPC

- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to bacterial strains, compositions comprising bacterial strains as well as methods and uses of said strains and compositions for use in boosting the immune system. More specifically, the invention relates to bacterial strains having immunomodulatory properties providing specific health benefits in a subject in need thereof.

## Claims

### Claim 1

A method for boosting an immune system in a subject in need thereof, wherein the method comprises administering to the subject an effective amount of a probiotic composition comprising one or more bacterial strains selected from the species Lactiplantibacillus plantarum, Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, Lacticaseibacillus casei, Streptococcus thermophilus, Lactobacillus gasseri, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus bulgaricus, Levilactobacillus brevis, Lactococcus lactis, Bifidobacterium longum subsp. infantis, Bifidobacterium animalis subsp. lactis, Bifidobacterium longum, Bifidobacterium bifidum, Ligilactobacillus salivarius, Limosilactibacillus fermentum and Limosilactibacillus reuteri.

### Claim at position 2

2-5. (canceled)

### Claim 6 (depends on 1)

The method according to claim 1, wherein said boosting of the immune system modulates the immune function.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the modulation of the immune system boosts anti-pathogen and/or anti-cancer immunity.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the modulation of the immune system boosts immunity against extracellular bacteria and fungi.

### Claim 9

(canceled)

### Claim 10 (depends on 7)

The method according to claim 7, wherein said boosting is due to activation of dendritic cells.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the dendritic cells activate T-cells.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the T-cells are T-helper cell type 1 (Th1) and/or T-helper cell type 17 (Th17) And/or regulatory T-cells (Treg).

### Claim 13 (depends on 1)

The method according to claim 1, wherein the boosting of the immune system modulates anti-viral immunity.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the modulation of the anti-viral immunity affects anti-viral response.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the modulation of the anti-viral immunity inhibits/controls the inflammation during the anti-viral response.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the modulation is due to the activation of macrophages.

### Claim 17

(canceled)

### Claim 18 (depends on 14)

The method according to claim 14, wherein the modulation is due to the activation of dendritic cells.

### Claim at position 16

19-20. (canceled)

### Claim 21 (depends on 1)

The method according to claim 1, wherein the boosting of the immune system results in antigen specific immune responses.

### Claim 22 (depends on 1)

The method according to claim 1, wherein the boosting of the immune system is due to activation of antigen presenting cells.

### Claim 23 (depends on 1)

The method according to claim 1, wherein the boosting of the immune system is due to activation of dendritic cells.

### Claim 24 (depends on 1)

The method according to claim 1, wherein the boosting of the immune system is due to activation of macrophages.

### Claim 25 (depends on 1)

The method according to claim 1, wherein;
the boosting of the immune system is due to activation of antigen presenting cells, dendritic cells and/or macrophages; and
the antigen presenting cells, dendritic cells and/or macrophages induce activation of antigen specific T cells.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the antigen specific T cells are T-helper cell type 1 (Th1) and/or T-helper cell type 17 (Th17) and/or regulatory T-cells (Treg).

### Claim at position 23

27-28. (canceled)

### Claim 29 (depends on 1)

The method according to claim 1, wherein:
the bacterial strains of the species Lactiplantibacillus plantarum are strains Lp-115, Lp12418 and/or Lp12407;
the bacterial strains of the species Lacticaseibacillus paracasei are strains Lpc-37 and/or Lc-10;
the bacterial strain of the species Lacticaseibacillus rhamnosus is strain Lr-32;
the bacterial strain of the species Lacticaseibacillus casei is strain Lc-11;
the bacterial strain of the species Streptococcus thermophilus is strain St-21;
the bacterial strain of the species Lactobacillus gasseri is strain Lg-36;
the bacterial strains of the species Lactobacillus acidophilus is strain La-14;
the bacterial strain of the species Lactobacillus crispatus is strain Lx1220;
the bacterial strain of the species Lactobacillus bulgaricus is strain Lb-87;
the bacterial strain of the species Levilactobacillus brevis is strain Lbr-35;
the bacterial strain of the species Lactococcus lactis is strain Ll-23;
the bacterial strain of the species Bifidobacterium longum subsp. infantis is strain Bi-26;
the bacterial strains of the species Bifidobacterium animalis subsp. lactis are strain B420 and/or Bi-07;
the bacterial strain of the species Bifidobacterium longum is strain B1-05;
the bacterial strain of the species Bifidobacterium bifidum is strain Bb-06;
the bacterial strain of the species Ligilactobacillus salivarius is strain Ls-33;
the bacterial strain of the species Limosilactibacillus fermentum is strain SBS-1; and
the bacterial strain of the species Limosilactibacillus reuteri is strain 1E1.

### Claim at position 25

30-33. (canceled)

### Claim 34 (depends on 1)

The method according to claim 1, wherein said composition is a food product, a food ingredient, a dietary supplement, a vaccine or a pharmaceutical acceptable composition.
